ArticleOncotarget2016
Zinc finger protein ZBTB20 is an independent prognostic marker and promotes tumor growth of human hepatocellular carcinoma by repressing FoxO1.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 30 citations in OpenAlex.
- Dual Regulatory Functions of Classical Zinc Finger Clusters from Myeloid Zinc Finger-1.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Dysregulation of the PATZ1/CTCF Balance Silences ZBTB20 to Drive Melanoma Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- ZBTB20 promotes ferroptosis through inhibiting TMEM109 expression in glioblastoma cells.International journal of oncology · 2025Article
- ZBTB20 suppresses tumor growth in glioblastoma through activating the TET1/FAS/caspase‑3 pathway.Oncology letters · 2024Article
- Zinc Finger and BTB Domain-Containing 20: A Newly Emerging Player in Pathogenesis and Development of Human Cancers.Biomolecules · 2024Review
- Article
- Transcription Factor Zbtb20 as a Regulator of Malignancy and Its Practical Applications.International journal of molecular sciences · 2023Review
- SPOP regulates the expression profiles and alternative splicing events in human hepatocytes.Open life sciences · 2023Article
- Article
- Article
- The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma.Cancers · 2021Review
- Massive parallel sequencing in a family with rectal cancer.Hereditary cancer in clinical practice · 2021Article
- Role of Forkhead Box O Proteins in Hepatocellular Carcinoma Biology and Progression (Review).Frontiers in oncology · 2021Review
- Zinc Finger Protein ZBTB20 protects against cardiac remodelling post-myocardial infarction via ROS-TNFα/ASK1/JNK pathway regulation.Journal of cellular and molecular medicine · 2020Article
- HBV DNA integrates into upregulated ZBTB20 in patients with hepatocellular carcinoma.Molecular medicine reports · 2020Article
- Primrose syndrome: Characterization of the phenotype in 42 patients.Clinical genetics · 2020Article
- Article
- MicroRNAs Regulating Cytoskeleton Dynamics, Endocytosis, and Cell Motility-A Link Between Neurodegeneration and Cancer?Frontiers in neurology · 2020Review
- Article
- Polydatin inhibits hepatocellular carcinoma via the AKT/STAT3-FOXO1 signaling pathway.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zinc finger and BTB domain-containing 20 (ZBTB20) is a new BTB/POZ-domain gene and a member of the POK family of transcriptional repressors. Notably, the role of ZBTB20 and its underlying mechanisms involved in hepatocarcinogenesis are poorly investigated. In this study, the expression of ZBTB20 was significantly overexpressed in hepatocellular carcinoma (HCC) tissues. The positive expression of ZBTB20 was associated with large tumor size, high Edmondson-Steiner grading and advanced tumor-node-metastasis (TNM) tumor stage. Additionally, HCC patients with positive expression of ZBTB20 had a poorer 5-year survival. Multivariate analyses revealed that ZBTB20 overexpression was an independent prognostic factor for HCC. Gain- and loss-of-function experiments demonstrated that ZBTB20 promoted HCC cell viability, proliferation, tumorigenicity, and cell cycle progression. Mechanistically, Cyclin D1 and Cyclin E were increased, while p21 and p27 were decreased by ZBTB20 in HCC cells. FoxO1 was inversely correlated with ZBTB20 protein expression in the same cohort of HCC specimens. We further revealed that FoxO1 was transcriptionally repressed by ZBTB20 in HCC. Moreover, restoration of FoxO1 expression partially abrogated ZBTB20-induced HCC cell proliferation and growth entry in vitro and in vivo. Collectively, these results indicate that ZBTB20 may serve as a prognostic marker and promotes tumor growth of HCC via transcriptionally repressing FoxO1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.